Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen To Market Biweekly Risperdal In Japan

This article was originally published in PharmAsia News

Executive Summary

Japan's Janssen Pharmaceutical plans to begin marketing in Japan a new injectable version of Risperdal (risperidone) for treating schizophrena by the end of June. The Johnson & Johnson subsidiary is counting on a biweekly injectable form of the drug to be more attractive to Japanese patients than a daily oral medicine now available. With the new version, Janssen also hopes to make a generic version of the daily drug less attractive. The biweekly version is to be marketed in Japan as Risperdal Consta. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts